Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…
VJOncology are thrilled to present our top picks from the the IASLC 2022 World Conference on Lung Cancer (WCLC) congress!
In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to…
VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!
As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide…
Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!
A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple…
VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium!